INTRODUCTION
Diabetes mellitus has emerged as a major healthcare problem in India. According to estimates, India has the highest number of adults with diabetes reported at 50.8 millions in 2010 which is expected to rise to 87 millions by 2030. [1] The prevalence of diabetes has been reported to be rapidly increasing in both rural and urban India. [2] An oral antidiabetic drug (OAD) is the first line of drug treatment for Type 2 diabetes. However, the progressive nature of Type 2 diabetes usually requires a combination of two or more oral agents in the long term. Safety and tolerability often limit the optimal use of OADs.
of dose normally used in man for diagnosis, prophylaxis, and treatment of disease or modification of physiological function." [4] A number of factors are in general responsible for ADRs including polypharmacy, drug interactions, and complexity of diseases.
Pharmacovigilance of antidiabetic drugs can play a crucial role in detecting ADRs and providing feedback to physicians on the possibility and details of such events, thereby protecting the patients from avoidable harm. [5] In India, pharmacovigilance activities are still in nascent stage and initiatives are being taken for spontaneous ADR reporting under the Pharmacovigilance Programme of India. However, in India, there are very few reports available on the ADR profile of antidiabetic agents in particular. Hence, this study aims to detect frequency and total burden of different adverse events due to OAD use in a diabetes outpatient department (OPD) of a medical college in Eastern India.
MATERIALS AND METHODS
A longitudinal observational study was conducted on Type 2 diabetes mellitus patients on oral hypoglycemic agents, attending Diabetes Clinic of College of Medicine and JNM Hospital, Kalyani, a tertiary care teaching hospital in West Bengal between April and September 2013. Patients receiving Insulin were excluded from the study.
All suspected ADRs were initially assessed by the Consultant Incharge -Diabetes Clinic and subsequently the information was collected and analyzed by the pharmacologists for causality assessment.
Patient details (age, sex, body weight), adverse event history, history of medication suspected of having caused the ADR, including its onset, duration, temporal association with drug intake if any and details of concomitant medication use, were recorded in the format followed in the Pharmacovigilance Programme of India. [6] The causality relationship among ADR and drug was assessed by the WHO-Uppsala Monitoring Centre (WHO-UMC) criteria. [7] Suspected ADRs with causality status less than "possible" were not analyzed further.
RESULTS
A total of 1000 patients were screened for the study, of which 276 (27.6%) were suspected of having at least one ADR from oral hypoglycemic agents. On causality assessment, 43 of these 276 cases (16.66%) were considered to have insufficient evidence about causality (WHO-UMC causality status "unlikely"), and they were excluded from further analysis. Out of the remaining 233 patients analyzed, 275 suspected ADRs were detected. Few patients had reported the presence of more than one ADR, either due to single drug use or due to multiple antidiabetic drug use. Thus, 23.30% (233) of our total subjects (1000) reported ADRs with atleast "Possible" Causality.
No ADR encountered turned out to be fatal, life-threatening, or required hospitalization for management. None of the ADRs was labeled "Certain" as rechallenge in the same dose, was not attempted by the attending physician, once a drug was withdrawn.
Out of 1000 patients, 562 were male, and 438 were female. The average age of the patients were 48.32 among 233 patients, who had ADR, 129 patients were male, and 104 were female. Percentage of ADR occurrence among all male patient was 22.95%, and among female, it was 23.74%.
Out of 1000 patients, 963 patients were given metformin; dose varied from 500 mg/day up to 2 g/day. Out of them, total 108 patients (11.21%) reported one or more adverse effect after use of this drug. Among them, there were 84 incidents of dyspepsia, 49 incidents of diarrhea, and 9 incidents of nausea, vomiting (Table 1) .
A total of 628 patients were given glimepiride in the study group; dose varied from 1 to 4 mg/day. Among them, 74 patients had some symptoms of hypoglycemia (sweating, tremor, palpitation, vertigo, and dizziness) and 6 patients complained about weight gain after the use of glimepiride. Hence, total 80 patients (12.74%) had some adverse event due to glimepiride use (Table 2 ).
A total of 67 patients were given voglibose for controlling postprandial hyperglycemia. Among them, 32 patients (47.76%) reported to have dyspepsia. 8 patients among those also had diarrhea.
Pioglitazone was given in 71 patients. 13 of them (18.31%) had complained about pedal edema. All of them occurred in the dose of 15 mg/day (Figure 1 ).
DISCUSSION
The present study has reported the incidence and attempted to profile suspected ADRs due to antidiabetic drugs in the diabetes OPD setting in the Indian context. In contrast to reports of ADR profiles of individual drugs, there is a dearth of pharmacovigilance profiling of antidiabetic agents in general in India, that too, keeping insulin out of the list. Hypoglycemia due to insulin is the most common adverse event reported in most of the drug utilization studies, [8] but our study aims for the common adverse events due to OADs
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only. Hence, it had dyspepsia as the most commonADR, not hypoglycemia.
In a study conducted in Italy, [9] Overall 148,289 ADR reports have been collected and, of these, 3416 (2.3%) were due to antidiabetic agents. The most reported serious ADRs were severe hypoglycemia (about 50% of serious ADR reports) , mainly caused by insulins or sulfonylureas, lactic acidosis from metformin, pancreatitis from incretins.
In that study, reported ADRs for sulfonylureas and biguanides were mainly metabolic disorders. Regarding alphaglucosidase inhibitors, glucagon-like peptide-1 mimetics and dipeptidyl peptidase-4 (DPP-4) inhibitors, gastrointestinal system was the most frequently affected site.
In our study also, dyspepsia and diarrhea were the most common adverse effect reported by patient to doctors, mostly due to metformin, followed by voglibose.
Glimepiride alone or its combination with metformin caused a few incidence of hypoglycemia, all of them have occurred if glimepiride was used with dose of 2 mg/day or more.
Metformin-induced dyspepsia occurred only if it was used in dose more than 1000 mg/day.
Incidence of dyspepsia was also common with use of voglibose, as expected from its mechanism of action. Metformin with voglibose combination produced more frequent incidents of dyspepsia.
This study have found a few cases of pedal edema with pioglitazone use, in dose of 15 mg. Higher than 15 mg dose for pioglitazone was not used. The patients who reported edema, their dose for pioglitazone was reduced to 7.5 mg/ day, which did not produce pedal edema to any of the subjects.
As obtained from the vigiflow data from India, [10] in the period 2010-2012, 466 cases of adverse events due to antidiabetics were reported. Average onset age (mean±standard error of mean) of male patients was 51.0 ± 0.72 and female patients 50.433 ± 0.72. It was found that 40% of ADR related to antidiabetics were occurred in female, whereas 60% in counterpart. 26% cases were found to be of the serious, Metabolic and nutritional disorders constituted 13%, gastrointestinal system disorders constituted 5% and central nervous system disorders constituted 4%. Two cases of hypoglycemia were responsible for the life-threatening condition during this period. One case of metformin-induced encephalopathy without metabolic syndrome was found which is the unexpected. In most of the cases, reporter was doctor.
In our study, out of 233 ADRs, 129 were reported by male and 104 were reported by female patients. There were no serious events recorded, may be due to insulin was kept out of the measurement, which is the most commont agent to cause fatal hypoglycemia. 
